Abstract
Despite recent advances, treatment of leukemia is often not curative. New insights indicate that this may be attributable to a small population of therapy-resistant malignant cells with self-renewal capacity and the ability to generate large numbers of more differentiated leukemia cells. These leukemia-initiating cells are commonly referred to as Leukemia Stem Cells (LSCs). LSCs are regarded as the root of leukemia origin and leukemia recurrence after seemingly successful therapy. Not surprisingly therefore, contemporary leukemia research has focused on ways to specifically eliminate LSCs, leading to the identification of several promising anti-LSC strategies. Firstly, LSCs may be eliminated by antibody- or ligand-based cell surface delivery of therapeutics such as naked antibodies, immunotoxins, and immunocytokines. This approach exploits LSC-associated surface antigens, such as CD33, CD44, CD96, CD123 and CLL-1 for LSC-selective therapy and aims to spare normal hematopoietic stem cells. A second strategy aims to disrupt the interactions between LSCs and their highly specialized niche. These interactions appear to be pivotal for maintenance of the stem cell-like characteristics of LSCs. A third strategy centers on the selective modulation of aberrantly activated signaling pathways central to LSC biology. A fourth strategy, dubbed ‘epigenetic reprogramming’, aims to selectively reverse epigenetic alterations that are implicated in ontogeny and maintenance of LSCs. In this review, we will discuss the rationale for these LSCs-targeted strategies and highlight recent advances that may ultimately help pave the way towards selective LSCs-elimination.
Keywords: Leukemia stem cells, AML, CML, targeting, apoptosis, antibody, epigenetics, Pregnancy, infliximab, adalimumab, certolizumab pegol, Crohn's disease, ulcerative colitis, inflammatory bowel disease
Current Drug Targets
Title: Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Volume: 11 Issue: 1
Author(s): B. ten Cate, M. de Bruyn, Y. Wei, E. Bremer, W. Helfrich, Marwa El Mourabet, Sandra El-Hachem, Janet R. Harrison and David G. Binion
Affiliation:
Keywords: Leukemia stem cells, AML, CML, targeting, apoptosis, antibody, epigenetics, Pregnancy, infliximab, adalimumab, certolizumab pegol, Crohn's disease, ulcerative colitis, inflammatory bowel disease
Abstract: Despite recent advances, treatment of leukemia is often not curative. New insights indicate that this may be attributable to a small population of therapy-resistant malignant cells with self-renewal capacity and the ability to generate large numbers of more differentiated leukemia cells. These leukemia-initiating cells are commonly referred to as Leukemia Stem Cells (LSCs). LSCs are regarded as the root of leukemia origin and leukemia recurrence after seemingly successful therapy. Not surprisingly therefore, contemporary leukemia research has focused on ways to specifically eliminate LSCs, leading to the identification of several promising anti-LSC strategies. Firstly, LSCs may be eliminated by antibody- or ligand-based cell surface delivery of therapeutics such as naked antibodies, immunotoxins, and immunocytokines. This approach exploits LSC-associated surface antigens, such as CD33, CD44, CD96, CD123 and CLL-1 for LSC-selective therapy and aims to spare normal hematopoietic stem cells. A second strategy aims to disrupt the interactions between LSCs and their highly specialized niche. These interactions appear to be pivotal for maintenance of the stem cell-like characteristics of LSCs. A third strategy centers on the selective modulation of aberrantly activated signaling pathways central to LSC biology. A fourth strategy, dubbed ‘epigenetic reprogramming’, aims to selectively reverse epigenetic alterations that are implicated in ontogeny and maintenance of LSCs. In this review, we will discuss the rationale for these LSCs-targeted strategies and highlight recent advances that may ultimately help pave the way towards selective LSCs-elimination.
Export Options
About this article
Cite this article as:
Cate ten B., de Bruyn M., Wei Y., Bremer E., Helfrich W., Mourabet El Marwa, El-Hachem Sandra, Harrison R. Janet and Binion G. David, Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology, Current Drug Targets 2010; 11 (1) . https://dx.doi.org/10.2174/138945010790031063
DOI https://dx.doi.org/10.2174/138945010790031063 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery PBX1 Participates in Estrogen-mediated Bladder Cancer Progression and Chemo-resistance Affecting Estrogen Receptors
Current Cancer Drug Targets ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Recent Advances in Rational Diagnosis and Treatment of Normal Pressure Hydrocephalus: A Critical Appraisal on Novel Diagnostic, Therapy Monitoring and Treatment Modalities
Current Drug Targets Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued) Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science The Role of Aromatase Enzyme in Hormone Related Diseases and Plant- Based Aromatase Inhibitors as Therapeutic Regimens
Current Topics in Medicinal Chemistry Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology A Review on Epigenetic Effects of Environmental Factors Causing and Inhibiting Cancer
Current Molecular Medicine Trans-Platinum Complexes with Promising Antitumor Properties
Medicinal Chemistry Reviews - Online (Discontinued) Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Current Medicinal Chemistry Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science